Michael Yee

https://assets.montefioreeinstein.org/profiles/images/13771-michael-yee.jpg

First Name

Michael

Last Name

Yee

NPI

1699971085

Faculty ID

13771

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5456

Is Open Scheduling

Off

Vlad A. Tomuta

https://assets.montefioreeinstein.org/profiles/images/9432-vlad-tomuta.jpg

First Name

Vlad

Last Name

Tomuta

NPI

1558537340

Faculty ID

9432

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5457

Is Open Scheduling

Off

Tihomir Stefanec

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/9bfe20f0-2346-11ee-88ab-4d123afddc94.jpg

First Name

Tihomir

Last Name

Stefanec

NPI

1396729976

Faculty ID

11731

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>I am interested in Internal Medicine, Critical Care Medicine and Pulmonary Medicine. &nbsp;My current interest is Critical Care Medicine. &nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Multidisciplinary Critical Care Medicine (Medical, Surgical, Neurologic, Cardiothoracic).<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Role of the endothelium and its progenitors in the pathogenesis of disease.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

5176

Biography

<p>Tihomir Stefanec, MD, is Attending Physician, Critical Care Medicine, Assistant Professor, Medicine and Neurology at Montefiore Einstein. His clinical focus is multidisciplinary critical care medicine including medical, surgical, neurologic and cardiothoracic critical care.</p><p>After earning his Doctor of Medicine from the University of Zagreb Medical School in Zagreb, Croatia in 1992, Dr. Stefanec completed an internal medicine internship and residency at Long Island College Hospital in 1997. He then completed a critical care medicine fellowship at Saint Vincent&rsquo;s Hospital and Medical Center in 1999. Following this, Dr. Stefanec completed a pulmonary medicine fellowship at Memorial Sloan Kettering Cancer Center in 2001.</p><p>Dr. Stefanec&rsquo;s past research focuses on the role of the endothelium and its progenitors in the pathogenesis of disease. His work has been published in peer-reviewed original publications, reviews, editorials and abstracts, and he has presented nationally.</p><p>Dr. Stefanec is board certified in Internal Medicine, Critical Care Medicine and Pulmonary Medicine by the American Board of Internal Medicine, as well as in Neurocritical Care by the United Council for Neurologic Subspecialties. He has been a Fellow of the American College of Chest Physicians since 2003, and is a member of the American Thoracic Society, the American College of Chest Physicians and the European Respiratory Society.</p>

Is Open Scheduling

Off

Alexander I. Sankin

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6a135040-3a87-11ed-8158-59ecbd24247c.jpg

First Name

Alexander

Last Name

Sankin

NPI

1982866570

Faculty ID

14891

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Sankin is an academic surgeon in the Department of Urology, at Montefiore Medical Center with a clinical focus on surgical approaches to the management of urologic malignancies of the upper urinary tract and bladder. His academic focus is divided between clinical and translational research studying emerging treatments and techniques central to the surgical care of patients with urologic cancers.&nbsp;</p>
<p>Dr. Sankin is the site-Principal Investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin speardeaded the development of a bladder cancer clinical trials program at Einstein.&nbsp;</p>
<p>His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therpeutic targets. &nbsp;</p>
<p>&nbsp;</p>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Sankin current research program focuses on the translational application of immune-oncology to the treatment of urologic cancer.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sankin's&nbsp;clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p align="left">Clark TW,&nbsp;Sankin A, Becske T, Nelson PK, Fox M.&nbsp;&nbsp;Stent-assisted Gugliemi detachable coil repair of wide-necked renal artery aneurysm using 3-D angiography.&nbsp;&nbsp;Vasc Endovascular Surg 2008 Jan; 41(6):528-32</p>
<p align="left">Tareen B,&nbsp;Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS.&nbsp;Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort<em>.</em>&nbsp;Urology.&nbsp;&nbsp;2009 Feb;73(2):351-4</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Laterality alone should not drive selection of candidates for hemi-ablative focal therapy.&nbsp;J Urol.&nbsp;&nbsp;2009 Mar;181(3):1082-9</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?&nbsp;&nbsp;BJU Int. 2009 Jul;104(2):195-9</p>
<p align="left">Marien T,&nbsp;Sankin A, Lepor H.&nbsp;&nbsp;Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;J Urol.&nbsp;&nbsp;2009 Apr;181(4):1817-22</p>
<p align="left">Sankin A, Tareen B, Lepor H.&nbsp;&nbsp;Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;Prostate Cancer Prostatic Dis.&nbsp;&nbsp;2009;12(2):204-8</p>
<p align="left">Mufarrij P,&nbsp;Sankin A, Godoy G, Lepor H.&nbsp;Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2010 Sep;76(3):689-92</p>
<p align="left">Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N.&nbsp;&nbsp;Rate of renal cell carcinoma subtypes in different races.&nbsp;&nbsp;Int Braz J Urol.&nbsp;&nbsp;2011 Feb;37(1):29-32</p>
<p align="left">Sankin A, Sfakianos J, Schiff J, Sjoberg D, Coleman J.&nbsp;Assessing renal function following partial nephrectomy using renal nuclear scintigraphy and eGFR.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2012 Aug;80(2):343-6</p>
<p align="left">Ghavamian R, Hakimi AA, Williams SK, Kim PH, Chen L, Sfakianos JP, Keren-Paz GE,&nbsp;Sankin A,&nbsp;Ginzburg N, Coleman JA.&nbsp;&nbsp;Factors affecting proportional glomerular filtration rate following minimally invasive partial nephrectomy.&nbsp;&nbsp;J Endourology&nbsp;&nbsp;2013 Nov;27(11):1371-5</p>
<p align="left">Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ.&nbsp;&nbsp;The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.&nbsp;&nbsp;Cancer Medicine 2014 Dec;3(6):1485-92</p>
<p align="left">Mano R, Vertosick E,&nbsp;Sankin A,&nbsp;Chevinsky M, Larish Y, Jakubowski CD, Hotker AM, Sjoberg D, Akin O, Russo P.&nbsp;&nbsp;The clinical significance of indeterminate pulmonary nodules in patients with renal cell carcinoma.&nbsp;&nbsp;J Urol 2014 Mar;193(3):776-82</p>
<p align="left">Chevinsky M, Imnadze M,&nbsp;Sankin A, Winer A, Mano R, Jakubowski C, Mashni J, Sjoberg DD, Chen YB, Tickoo SK, Reuter VE, Hakimi AA, Russo P.&nbsp;Pathologic stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma.&nbsp;J Urol 2015 Aug;194(2):310-5</p>
<p align="left">Hakimi AA, Tickoo S, Jacobsen A, Sarungbam J, Sfakianos J, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB,&nbsp;Sankin A,&nbsp;Mano R, Coleman JA, Russo P, Ogawa S, Sander C, Hsieh JJ, Reuter VE.&nbsp;TCEB1-mutated renal cell carcinoma: a distinct genomic and morphologic subtype.&nbsp;&nbsp;Mod Pathol 2015 June;28(6):845-53</p>
<p align="left">Sankin A,&nbsp;Hakimi AA, Hsieh JJ, Molina AM.&nbsp;&nbsp;Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.&nbsp;&nbsp;Front Oncol 2015 Apr 8;5:67</p>
<p align="left">Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R,&nbsp;Sankin A, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, Choueiri TK, Hsieh JJ, Klein RJ.&nbsp;&nbsp;Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell&nbsp;carcinoma.&nbsp;&nbsp;Cancer 2016 Feb 1;122(3):402-10</p>
<p align="left">Sankin A. Discovering biomarkers within the genomic landscape of renal cell carcinoma.&nbsp;&nbsp;J Kidney 2016 Feb 2(1)&nbsp;</p>
<p align="left">Sankin A, Tin A, Mano R, Chevinsky M, Jakubowski C, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman J.&nbsp;&nbsp;Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes.&nbsp;&nbsp;Urology 2016 Aug; 94:148-53</p>
<p align="left">Mano R, Hakimi AA,&nbsp;Sankin AI,&nbsp;Sternberg IA, Chevinsky MS, Russo P.&nbsp;&nbsp;Surgical treatment of tumors involving kidneys with fusion anomalies &ndash; a contemporary series.&nbsp;&nbsp;Urology 2016 Aug; 98:97-102</p>
<p align="left">Zhou TC,&nbsp;Sankin A,&nbsp;Porcelli SA, Perlin DS, Schoenberg MP, Zang XX.&nbsp;&nbsp;A review of the PD-1/PD-L1 checkpoint in bladder cancer: from mediator of immune escape, to target for treatment.&nbsp;&nbsp;Urol Oncol 2017 Jan;35(1):14-20&nbsp;</p>
<p align="left">Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD,&nbsp;Sankin AI,&nbsp;Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.&nbsp;Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.&nbsp;&nbsp;Urol Oncol 2017 April;35(4):151</p>
<p align="left">Sankin&nbsp;A,&nbsp;Narasimhulu&nbsp;D, John P,&nbsp;Gartrell&nbsp;B, Schoenberg M, Zang XX.&nbsp; The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1.&nbsp;&nbsp;Urol&nbsp;Onc&nbsp;2017 (Epub ahead of print)</p>
<p align="left">Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T,&nbsp;Sankin A,&nbsp;Pierorazio PM, Schoenberg MP, Bivalacqua TJ. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer.&nbsp;&nbsp;Bladder Cancer 2017 Oct 27;3(4):293-303</p>
<p align="left">Daneshmand S, Patel s, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O&rsquo;Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS,&nbsp;Flexible Blue Light Study Group Collaborators.&nbsp;Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.&nbsp;&nbsp;J Urol 2018 May;199(5):1158-65</p>
<p align="left">Fridman D, Abeshouse M,&nbsp;Sankin A.&nbsp;Paraurethral Leiomyoma as an Incidental Finding in a Patient with Fibroid Uterus. Case Rep Obstet Gynecol 2018 Feb 7;2018</p>
<p align="left">Adrianzen Hererra DA, Goldberg-Stein S,&nbsp;Sankin A, Sarungbam J, Sharma J, Gartrell BA. Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies. Front Oncol, 2018 Apr 30;8:137</p>
<p align="left">Berstein A, Fram EB,&nbsp;Sankin A, Kovac E, Srivastava A, DiVito J, Stern JM. A Comparison of Perinephric Fat Surface Area and Mayo Adhesive Probability Score in Predicting Malignancy in T1 Renal Masses.&nbsp;&nbsp;Urol Onc 2018 Nov; 36(11):499</p>
<p align="left">Sun Y, Reuter VE, Magi-Galluzzi C,&nbsp;Sankin A,&nbsp;Epstein JI.&nbsp;Granular Cell Tumor of the Bladder: A Report of Six Cases.&nbsp;&nbsp;Urology 2018 Nov; 121:203&nbsp;</p>
<p align="left">Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ,&nbsp;Sankin A,&nbsp;Schoenberg MP, Shipley WU, Villers A, Efstathiou J, Bellmunt J, Stenzl A.&nbsp;&nbsp;Recommendations From Joint SIU-ICUD Consultation On Bladder Cancer: Muscle-Invasive Presumably Regional Tumor.&nbsp;&nbsp;World J Urol 2019, Jan;37(1): 61-83</p>
<p align="left">Chand D, Dhawan D,&nbsp;Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X. Immune checkpoint B7x (B7-H4/B7S1/VtCN1) is overexpressed in spontaneous canine bladder cancer: the first report and its implications in a preclinical model. Bladder Cancer 2019, Jan 31;5(1)63-71</p>
<p align="left">Bernstein A, Barry E, Fram EB,&nbsp;Sankin A,&nbsp;Kovac E, Stern JM.&nbsp;Does Glomerular Filtration Rate at Discharge After Partial Nephrectomy Predict Long-Term Glomwerular Filtration Rate Stability?. J Endourol 2019, Jun;33(6):488-491</p>
<p align="left">Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat A, Konety B, Malmstrom PU, McKiernan J, O&rsquo;Donnell M, Patel S, Pohar K, Resnick M,&nbsp;Sankin A,&nbsp;Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.&nbsp;&nbsp;Blue light flexible cystoscopy with hexaminolevulinate in non-muscle invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA &ndash; update 2018. Nat Rev Urol 2019, Jun;16(6):377-386</p>
<p align="left">Sankin A,&nbsp;Chand D, Schoenberg M, Zang X.&nbsp;&nbsp;Human urothelial bladder cancer generates a clonal immune response: the results of T-cell receptor sequencing.&nbsp;&nbsp;Urol Oncol 2019, May 15 (epub ahead of print).</p>
<p align="left">Wang H, Kaur G,&nbsp;Sankin A,&nbsp;Chen F, Guan F, Zang X.&nbsp;Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.&nbsp;&nbsp;J Hematol Oncol 2019, Jun 11;12(1):59</p>
<p align="left">Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ,&nbsp;Sankin A, Kates M.&nbsp;&nbsp;Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 2019, Jun 26 (epub ahead of print)</p>
<p align="left">Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ,&nbsp;Sankin A, Kates M. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle invasive bladder cancer.&nbsp;&nbsp;Urol Oncol 2019, Aug 28 (epub ahead of print)</p>
<p align="left">Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Holmes CJ, Shreck E, Assi H, Gartrell BA, Sankin A,&nbsp;Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.&nbsp;&nbsp;Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.&nbsp;&nbsp;Cancer 2019, Dec 12 (epub ahead of print)</p>

EMR ID

78143

Biography

<p>Alexander I. Sankin, MD, is Associate Professor, Urology at Montefiore Einstein. His clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.</p><p>After earning his Master of Science from the University of Pennsylvania in 2004, Dr. Sankin earned his Doctor of Medicine from New York University in 2008 and completed his residency in surgery and urology at the State University of New York Downstate in 2013. He then completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in 2015.</p><p>Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer. He is the site-principal investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums, including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin spearheaded the development of a bladder cancer clinical trials program at Einstein. His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therapeutic targets. His work has been published in numerous peer-reviewed journals.</p><p>Dr. Sankin is board certified and a member of the American Urological Association and the Society of Urologic Oncology.</p>

Is Open Scheduling

Off

Samuel J. Rednor

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Samuel

Last Name

Rednor

NPI

1265775167

Faculty ID

16224

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Nephrology and Critical Care.

Research Focus

Dr. Rednor&rsquo;s research focus is in acute kidney injury (AKI), cardiac arrest, and intubation.&nbsp;

Elsevier Profile

EMR ID

87716

Biography

<p>Samuel J. Rednor, DO, is Director of Wellness, Critical Care and Assistant Professor, Medicine at Montefiore Einstein. His clinical focus is nephrology and critical care.</p><p>After earning his Doctor of Osteopathic Medicine at Lake Erie College of Osteopathic Medicine in 2013, Dr. Rednor completed his residency in internal medicine at Southampton Hospital in 2016, where he was Chief Resident for one year. He then completed his renal fellowship at Montefiore in 2018, where he was Chief Renal Fellow during his last year. Dr. Rednor went on to complete an additional fellowship at Montefiore in critical care, which he completed in 2019.</p><p>Dr. Rednor&rsquo;s research focus is in acute kidney injury (AKI), cardiac arrest, and intubation. His work has been published in peer-reviewed journals and he has given multiple lectures and presentations.</p><p>Dr. Rednor is board certified in Internal Medicine, Nephrology and Critical Care Medicine by the American Osteopathic Board of Internal Medicine. He is a member of the American Society of Nephrology (ASN), the American Osteopathic Association (AOA), the Society of Critical Care Medicine (SCCM) and the American College of Chest Physicians (CHEST). In 2018, Dr. Rednor won the Sharon R. Silbiger Teaching Award for excellence in teaching and in recognition as Outstanding Fellow of the Year from Einstein.</p>

Is Open Scheduling

Off

Marjan Rahmanian

https://assets.montefioreeinstein.org/profiles/images/physphoto/Rahmanian_Marjan_MD_420x504.jpg

First Name

Marjan

Last Name

Rahmanian

NPI

1033374434

Faculty ID

13978

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span>Dr. Marjan Rahmanian is an Assistant Professor of Medicine and Neurology. She is an Associate Medical Director of Cardiothoracic Intensive Care Unit at Montefiore Medical Center. She is also Medical Director of Physician Assistant Critical Care Residency program. She completed her Internal Medicine residency at Hackensack Meridian Mountainside Medical Center, followed by a fellowship in Critical Care Medicine at Mount Sinai Medical Center. After completing her training, she joined the faculty of the Albert Einstein College of Medicine in New York, where she served as an Associate Director of Cardiothoracic Surgical ICU at Montefiore Medical center. As a cardiac intensivist, Dr. Rahmanian focuses on the management of post heart surgery like CABG, valve replacemant, Mechanical Circulatory Support like,ECMO, LVAD,Impella, heart and lung transplant.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<ol>
<li>Maintaining Hemodynamic and Metabolic Homeostasis in Anheptaic Critically Ill Patients. Khan R, Go R, Kapoor S, Dharshan A, <strong>Marjan</strong> <strong>Rahmanian </strong>, Manasia A, Bassily-Marcus A, Kohli-Seth R, Oropello J, Benjamin E. CHEST. October 2012;142:390A-390A</li>
<li>The Heart Point Sign: An Ultrasonographic Confirmation Of Pneumothorax. R. Khan, M. <strong>Marjan</strong> <strong>Rahmanian</strong>, M. Kaufman, A. Bassily Marcus, J. Oropello. ajrccm-conference.2013.187.1 MeetingAbstracts.A1539</li>
<li>Cardiothoracic Surgical ICU Boot Camp can improve cardiovascular critical care knowledge among trainees. <strong>Marjan Rahmanian, </strong>MD; Lewis Eisen, MD; Adam Keene, MD; Rosemarie Conigliaro, MD; Anthony Carlese, DO ATS2018 Poster Presentation </li>
<li>Midodrine: Breaking New Ground in The Treament of Chylothorax: Dolly Patel, DO; <strong>Marjan Rahmanian, </strong>MD; Javed Iqbal, MD; Scott Scheinin, MD; Joshoua Lee, MD; Harish Seethamraju, MD Chest 2019 Poster Presentation</li>
<li>Lactate Dehydrogenase is Associated with Hemorrhagic Stroke During Extracorporeal Membrane Oxygenation for COVID-19 <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Saeed, O.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Uehara, M.</a>; <strong>Marjan</strong> <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank"><strong>Rahmanian</strong>.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Chen, J. T.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Carlese, A.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Mohamed, A.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Ashley, J.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Mellas, N.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Forest, S.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Goldstein, D.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Jorde, U.</a>.<em>ASAIO Journal ; 68(Supplement 3):19, 2022.</em></li>
<li><a href="https://einstein.pure.elsevier.com/en/publications/hiv-dr-heartkidney-t…; target="_blank">HIV D+/R+ heart/kidney transplantation: First case report</a> <a href="https://einstein.pure.elsevier.com/en/persons/vagish-s-hemmige&quot; target="_blank">Hemmige, V.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/omar-saeed&quot; target="_blank">Saeed, O.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/yoram-a-puius&quot; target="_blank">Puius, Y. A.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/yorg-al-azzi&quot; target="_blank">Azzi, Y.</a>, Colovai, A., Borgi, J., <a href="https://einstein.pure.elsevier.com/en/persons/daniel-j-goldstein&quot; target="_blank">Goldstein, D. J.</a>, Marjan Rahmanian, <a href="https://einstein.pure.elsevier.com/en/persons/anthony-j-carlese&quot; target="_blank">Carlese, A.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/ulrich-p-jorde&quot; target="_blank">Jorde, U. P.</a> &amp; <a href="https://einstein.pure.elsevier.com/en/persons/snehal-r-patel&quot; target="_blank">Patel, S. R.</a>, Mar 2023, In: <a href="https://einstein.pure.elsevier.com/en/persons/anthony-j-carlese&quot; target="_blank">Journal of Heart and Lung Transplantation.</a> 42, 3, p. 406-408 3 p. </li>
<li>Chest Tube Insertion, Needle Thoracostomy, And Pericardiocentesis During In-hospital Cardiac Arrest <a title="Luke Andrea" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Luke Andrea</a>, Marjan Rahmanian, <a title="Anthony Carlese" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Anthony Carlese</a>, <a title="Ariel Shiloh" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Ariel Shiloh</a>, <a title="Rithvik Balakrishnan" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Rithvik Balakrishnan</a>, <a title="Aron Soleiman" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Aron Soleiman</a>, <a title="Michelle Gong" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Michelle Gong</a> and <a title="Ari Moskowitz" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247&quot; target="_blank">Ari Moskowitz</a> Circulation. 2022;146:A247</li>
</ol>

EMR ID

5749

Is Open Scheduling

Off

Erin L. Ohmann

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/8ad52610-8315-11ed-bb08-39bbd9d39d57.jpg

First Name

Erin

Last Name

Ohmann

NPI

1548551781

Faculty ID

16467

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Clinical focus is general urology with a special interest in endourology and male and female voiding dysfunction.</span><quillbot-extension-portal></quillbot-extension-portal>

Research Focus

<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;">Dr. Ohmann is a frequent contributor to medical publications and abstracts in the area of benign urology, and her work has been published in several peer-reviewed publications.</span><quillbot-extension-portal></quillbot-extension-portal>

EMR ID

115672

Biography

<p>Erin Ohmann, MD, is an attending physician and Assistant Professor of Urology at Montefiore Einstein. Her clinical focus is general urology with a special interest in endourology and male and female voiding dysfunction. She specializes in treating conditions such as benign prostatic hypertrophy, urinary retention, urinary incontinence, overactive bladder, kidney stones, bladder stones, bladder cancer and prostate cancer.</p><p>After graduating from Cornell University with a Bachelor of Science degree, she received her medical degree from the University of Pittsburgh School of Medicine. While in medical school, she participated in the Doris Duke Clinical Research Program and earned a Master of Science in Clinical Research. Dr. Ohmann then completed surgical internship and urology residency at New York University Langone Medical Center.</p><p>Dr. Ohmann is a frequent contributor to medical publications and abstracts in the area of benign urology, and her work has been published in several peer-reviewed publications.</p><p>Dr. Ohmann is board certified in urology and is a fellow of the Jewish Healthcare Foundation Patient Safety. She is a member of the American Urological Association and Alpha Omega Alpha Honor Medical Society. She has received numerous awards and honors for her work.</p>

Is Open Scheduling

Off

Amira M. Mohamed

https://assets.montefioreeinstein.org/profiles/images/physphoto/Mohamed_Amira_MD_420x504.jpg

First Name

Amira

Last Name

Mohamed

NPI

1437560570

Faculty ID

16255

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Amira Mohamed completed her medical school education in Khartoum, Sudan before moving to the United States. She completed an internal medicine residency and sub-specialized in Critical Care Medicine after which she joined Montefiore Medical Center in 2019.<br />Dr. Mohamed became involved in the medical education of both internal medicine residents and critical care medicine fellows soon after joining Montefiore and was appointed the Associate Program Director of the Critical Care Medicine Fellowship Program in early 2021. She rebuilt the fellow curriculum and strengthened their involvement in non-clinical duties such as research and quality improvement. She became the Program Director in 2022.<br />Outside of medical education, Dr. Mohamed is the Associate Director of the Medical Intensive Care Unit at the Moses campus and her research interests include vaccine effectiveness and healthcare disparities.

Research Focus

Amira Mohamed is an intensivist with a specific interest in Acute Respiratory Distress Syndrome (ARDS) and respiratory failure. As the Associate Director of the Medical Intensive Care Unit at the Moses campus, she is involved in multiple quality improvement projects such as ventilator liberation with spontaneous awakening and breathing trials and measures to decrease Central Line Associated Blood Stream Infections.<br />As an intensivist and a clinical educator, Dr. Mohamed's focus has been on resident and fellow education. She has contributed to the recent changes in the Critical Care Curriculum with a renewed focus on research and quality improvement. During the COVID-19 pandemic, Dr. Mohamed joined the ICY network in a CDC-funded study of vaccine effectiveness and has published multiple studies on this topic.

Elsevier Profile

EMR ID

113279

Biography

<p>Amira Mohamed, MD, is Director, Critical Care Fellowship Program, Associate Director, Medical Intensive Care Unit, Moses Campus and Assistant Professor, Medicine at Montefiore Einstein. Dr. Mohamed is an intensivist with a specific interest in Acute Respiratory Distress Syndrome (ARDS) and respiratory failure.</p><p>After completing her medical school education in Khartoum, Sudan in 2012, Dr Mohamed later moved to the United States. She completed her internal medicine residency at Mount Sinai Medical Center in 2017, followed by a critical care medicine fellowship at Mount Sinai Hospital, Icahn School of Medicine in 2019, acting as Chief Fellow in her final year.</p><p>Dr. Mohamed&rsquo;s research interests include vaccine effectiveness and health care disparities. As an intensivist and a clinical educator, Dr Mohamed's focus has been on resident and fellow education. She has contributed to recent changes of the critical care curriculum at Montefiore Einstein, with a renewed focus on research and quality improvement. She has shared her research through peer-reviewed journals, book chapters and abstracts.</p><p>Dr. Mohamed is board certified in Internal Medicine and Critical Care Medicine. She is a member of the American Thoracic Society, the Society of Critical Care Medicine and the Association of Pulmonary and Critical Care Medicine Program Directors.</p>

Is Open Scheduling

Off

Franklin C. Lowe

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/1c4ff810-6315-11ee-bd4e-3d8872337956.jpg

First Name

Franklin

Last Name

Lowe

NPI

1801971270

Faculty ID

14708

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Treatment of benign and malignant disorders of the prostate.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Urological topics<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

73230

Biography

<p>Franklin C. Lowe, MD, Professor of Urology and Vice-Chair of the Department, is also Director of Urologic Services, Jack D. Weiler Hospital. An expert in the treatment of benign and malignant disorders of the prostate, Dr. Lowe has published over 150 articles on multiple urological topics and has lectured extensively throughout the world. Prior to joining The Department of Urology at Montefiore, Dr. Lowe held faculty and leadership positions at Columbia University, Mount Sinai School of Medicine and at St. Luke&rsquo;s/ Roosevelt Hospital in Manhattan. A Graduate of Princeton University, Dr. Lowe obtained both his Medical and Masters of Public Health degrees from Columbia University College of Physicians and Surgeons. He completed his internship and residency in Surgery and Urology at The James Buchanan Brady Urological Institute of Johns Hopkins University. Dr. Lowe previously served as the Chairman of The American Urological Association&rsquo;s Alternative Medicine Committee and as a member of the BPH Guidelines Committee.</p>

Is Open Scheduling

On

Matthew Levitus

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Matthew

Last Name

Levitus

NPI

1205219425

Faculty ID

16738

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

13410

Is Open Scheduling

Off